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SINAM: A Rare Case Leading to Respiratory Failure
D. Christine Hermiz, DO; Patrick Bradley, MD
Henry Ford Health System, Detroit, Michigan
Learning Objectives

A

Discussion (Continued)

• Understand the clinical course of statin-induced necrotizing
autoimmune myopathy (SINAM)
• Review the evaluation of suspected SINAM during statin
administration
• Identify evidence-based therapies that may aid in reversing this
potentially fatal myopathy

Introduction
Statins are commonly prescribed in primary care offices daily; however,
they are not exempt from adverse effects. Statin-induced myopathies are best
described on a continuum, as patients can range widely in presentation. The
most extreme of cases displaying respiratory distress, quadriparesis, dysphagia,
and rhabdomyolysis. Cases on the severe end of the spectrum with respiratory
failure are exceedingly rare and should be shared with the medical community in
order to gain more insight into the types of statins most at risk for causing
complications, most effective treatments based on disease severity, as well as
characteristics and objective findings among affected patients in order to
diagnose and treat in a time-effective manner.

Figure B: MRI L gluteus minimus edema.
Profound muscular edema displayed as increased signal of the L gluteus minimus (red
arrow) characteristic of myositis. A common finding in those with statin induced necrotic
myopathy.

B

This then begs us to consider, are all cases treated similarly? On the
already murky topic of a standardized treatment regime for a rare disease, it is
important to consider treating these patients based on severity of disease
symptoms. It is standard of care for SINAM to stop the offending statin and
begin immunosuppressive therapy. Treatment consists of prednisone with either
methotrexate, azathioprine, or mycophenolate mofetil [1, 2], a third agent (IVIG
or rituximab) can be added in severe cases; patients who received two or more
immunosuppressive agents showed better outcomes [1, 2, 4]. In many studies,
IVIG showed more favorable responses within the first 3 months of initiating
treatment, however, its benefit seemed to dissipate after the 6 month mark [3, 4].
For patients presenting with severe weakness and/or dysphagia, IV
methylprednisolone is recommended for 1-3 days with transition to high-dose
oral steroids with taper, IVIG for 1-6 months, and a third agent such as
cyclophosphamide, rituximab, or cyclosporine [3]. Rituximab has shown a great
deal of benefit in many studies for its ability to increase muscle function and
reduce immune-mediated muscular damage [3]. It is unknown the optimal
dosage or combination of therapy that would be the most efficacious treatment,
however, many studies have shown promise when using the agents described
above. Due to the autoimmune nature of SINAM, relapses occurred often when
immunosuppression is weaned or discontinued [1, 2, 4] and patients likely will
require a life-long steroid-sparing agent [4]. There is no agreed upon
maintenance therapy for these patients unable to be weaned off of
immunosuppression and further studies are needed to answer this question.

Case Description

Conclusion
The patient was a healthy, physically active 79-year-old male with past
medical history of CVA in 2018 without residual deficits, controlled type 2
diabetes, HTN, and sleep apnea on CPAP presenting in February of 2020 with
worsening quadriparesis, dysarthria, and dyspnea over the past 3 months.
Physical exam revealed extreme muscle weakness of 3/5 in upper extremities,
4/5 in lower extremities, unable to raise arms above a 45 degree angle, normal
cranial nerve exam. CT of the head/ neck was negative, moderate stenosis in
carotid US of 50-60%, and MRI of head showing no acute changes. CPK
elevated over 4,000 with elevated AST &ALT in the 300s. Autoimmune work
up was nonrevealing. EMG showed possible myopathy vs motor axonal
polyradiculoneuropathy vs demyelinating polyneuropathy. Treatment was
conservative and discharged to subacute rehab (SAR).
Over the course of 2 weeks at SAR, his weakness progressed with CPK
>7,000 with continued elevated liver function prompting a transfer to Henry
Ford for escalation of care in March of 2020. An exhaustive work up was
completed with negative autoimmune panel and EMG showing chronic
myopathy. History revealed he had been maintained on Atorvastatin 20 mg
after his CVA in October of 2018 and began to manifest weakness in December
2019 with discontinuation in February 2020. MRI revealed diffuse muscular
edema (Figure A). He was initially treated conservatively with intravenous
fluids and over the course of 7 days had progressive dyspnea and dysphagia
leading to respiratory failure and intubation. Muscle biopsy (Figure B) with
anti-HMGCr IgG confirming statin-induced necrotizing myopathy. He was
promptly treated with IV solumedrol for 5 days with transition to 60 mg
prednisone daily with IVIG 2g/kg x 5 days. Despite treatment, the patient
continued to decline with increasing CPK and inability to liberate from the
ventilator. Given his prior wishes was terminally weaned per family request
and passed soon after.

Figure B: Muscle necrosis on H&E stain.
Areas of patchy white are necrotizing muscle cells (black arrow) surrounded by
unaffected areas of normal muscle. [6]

Discussion
The rapid decline of an otherwise healthy patient should prompt further inquiry
as to the most efficacious treatment regimens; however, making the diagnosis can be
challenging as it is a rare condition with a prevalence in less than 1% of statincompliant patients. SINAM patients typically present with progressively worsening
symmetrical proximal muscle weakness with CK levels in the thousands despite
discontinuation of statins [1, 7]. Other findings include MRI showing muscle edema,
atrophy, and/or fatty infiltration, positive anti-HMGCr, EMG positive for myopathy,
and muscle biopsy displaying active necrosis [2]. Several case reports show widely
varying time courses of 2 months to 10 years after the initiation of statin therapy to
symptomatic necrotizing myopathies [2, 7]. Therefore, SINAM should be considered
as a differential in the patient with new onset myopathies with past or current use of
statins. The type of statins most likely to cause this condition were Atorvastatin,
Simvastatin, Lovastatin, and Fluvastatin due to their lipophilic nature and ability to
enter muscle cells [2]. Many patients are diagnosed when their most debilitating
symptom is proximal muscle weakness; however, retrospective studies have shown
that up to one-third of autoimmune myopathy cases had respiratory complications
with 5 of these patients requiring intubation [4]. Our patient was unique in that
despite the use of aggressive immunosuppression progressed to respiratory failure. To
date there are no reported cases of death due to SINAM.

Our patient presented with statin-induced necrotizing autoimmune
myopathy that progressed to respiratory failure. SINAM is a rare complication
of statin therapy that has high morbidity with rare mortality. SINAM should be
on the differential in patients presenting with new onset progressive weakness
who have been exposed to statin therapy. The mainstay of treatment is
immunosuppressive therapy; however, the optimal regimen and duration is
unknown and further studies are required to discern optimal treatment.

Bibliography
1. Hamann, P.D.H., Cooper, R.G., McHugh, N.J., Chinoy, H. Statin- induced necrotizing myositis –
a discrete autoimmune entity within the “statin- induced myopathy spectrum”. Autoimmunity
Reviews. 2013; 12 (12): 1177- 1181. https://doi.org/10.1016/j.atherosclerosis.2011.11.005
2. Babu, S., Li, Y. Statin induced necrotizing autoimmune myopathy. Journal of the Neurological
Sciences. 2015; 351 (1-2): 13-17. https://doi.org/10.1016/j.jns.2015.02.042
3. Ernste, F.C., Reed, A.M. Idiopathic Inflammatory Myopathies: Current Trends in Pathogenesis,
Clinical Features, and Up- to- Date Treatment Recommendations. Mayo Clinic Proceedings.
2012; 88 (1): 83-105. https://doi.org/10.1016/j.mayocp.2012.10.017
4. Kassardijan, C.D., Lennon, V.A., Alfugham, N.B., Mahler, M., Milone, M. Clinical Features and
Treatment Outcomes of Necrotizing Autoimmune Myopathy. JAMA Neurology. 2015; 72 (9) 9961003. Doi:10.1001/jamaneurol.2015.1207
5. Albayda, J., Christopher-Stine, L. Identifying stain- associated autoimmune necrotizing
myopathy. Cleveland Clinic Journal of Medicine. 2014; 81 (12): 736-741.
6. Sweidan, A. J., Leung, A., Kaiser, C. J., Strube, S. J., Dokukin, A. N., Romansky, S., & Farjami,
S. (2017). A Case of Statin-Associated Autoimmune Myopathy. Clinical medicine insights. Case
reports, 10, 1179547616688231. https://doi.org/10.1177/1179547616688231
7. Padala, S. Thompson, P.D. Statins as a possible cause of inflammatory and necrotizing
myopathies. Atherosclerosis, 2012; 222 (1): 15-21.
https://doi.org/10.1016/j.atherosclerosis.2011.11.005

